THE APEX TIMES
HCA Healthcare to buy CHCP, betting on education to expand its healthcare workforce pipeline
The Nashville-based hospital operator agreed to acquire ownership of The College of Health Care Professions (CHCP), a Texas allied-health training provider, as it looks to strengthen programs that prepare nurses and other non-physician clinicians.
HCA Healthcare (NYSE: HCA) said it has agreed to acquire ownership of The College of Health Care Professions (CHCP), aiming to expand its in-house ability to train healthcare workers and feed a growing pipeline of staff into its hospitals and other care sites.
In an announcement dated May 27, 2026, HCA said CHCP provides healthcare education to more than 8,000 students annually through 10 campuses in Texas and online. The college, founded in 1988, said it has prepared more than 52,000 students for healthcare careers and emphasizes programs designed for adult learners.
HCA described CHCP as a provider of allied healthcare training, meaning non-physician clinical roles that support patient care, such as medical assisting, imaging and certain technical specialties. CHCP’s offerings include more than 20 accredited programs, including Medical Assisting, Sonography, Surgical Technology, Radiologic Technology, and Medical Coding and Billing. The company also said CHCP offers hybrid, on-campus, and online options intended to let students balance work, family and other responsibilities.
The companies said they have already worked together. HCA said that in 2023 it collaborated with CHCP on a 12-week Medical Assistant training program for colleagues at HCA’s urgent care centers across Texas. HCA reported that since the program launched, more than 100 colleagues have graduated and increased career opportunities within HCA.
Leadership will remain in place at CHCP after the deal. HCA said Eric Bing will continue to lead CHCP as Chancellor and CEO. HCA CEO Sam Hazen said the acquisition is intended to strengthen the “talent pipeline” that serves patients and communities, while Bing said the transaction will carry forward shared goals around adult learner success, academic quality and workforce readiness.
The agreement fits HCA’s broader pattern of investing in nursing and workforce development. HCA said it acquired majority ownership in Galen College of Nursing in 2020, later opening 20 new campuses for a total of 25 campuses nationwide. HCA also said it operates Research College of Nursing in Kansas City, Missouri, and HCA Florida Mercy College of Nursing in Miami, and supported the launch of Pepperdine University’s School of Nursing within the College of Health Sciences in 2025.
The HCA statement added that the company’s foundation has supported education-access initiatives in Texas and Florida, including grants to Educate Texas and the Consortium of Florida Education Foundations intended to increase student access to healthcare career pathways.
HCA did not disclose the transaction terms, price, expected timeline, or the anticipated timing for regulatory approval. The company said the acquisition is subject to regulatory approval and customary closing conditions. With those details still unavailable, it is unclear how CHCP’s program mix, campus footprint, or integration into HCA’s broader education strategy may change before or after closing.
Why It Matters
- The acquisition indicates HCA’s effort to address workforce bottlenecks by building training capacity rather than relying only on external hiring.
- By adding an allied-health education platform alongside its nursing education investments, HCA is broadening its strategy beyond nursing into multiple technician and support roles.
- For students and employers, the deal could reshape career pathways by potentially expanding clinical training and placement opportunities tied to HCA facilities.
- Regulatory approval and deal integration are key uncertainties, especially given that HCA did not disclose financial terms or a closing timeframe.
Sources
Key Facts
- HCA Healthcare agreed to acquire ownership of The College of Health Care Professions (CHCP).
- CHCP said it educates more than 8,000 students annually across 10 Texas campuses and online.
- HCA said CHCP has prepared more than 52,000 students since opening in 1988 and offers more than 20 accredited programs.
- HCA reported that a 2023 CHCP collaboration, a 12-week Medical Assistant training program for HCA urgent care staff in Texas, produced more than 100 graduates.
- Eric Bing will continue to lead CHCP as Chancellor and CEO after the acquisition.
- HCA said the deal is subject to regulatory approval and customary closing conditions, and it did not disclose transaction terms.
Healthcare Related
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.
Eli Lilly shares slide after report of a $2.9 billion acquisition
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
Healthcare’s best week since late June draws focus to a Moderna and Merck cancer trial
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.
Pfizer highlights Padcev while pushing forward PF-08634404 as part of its longer-term oncology plan
A new market report frames Pfizer’s near-term oncology momentum around Padcev, while pointing to PF-08634404 and potential label expansion efforts as catalysts the company expects to matter later.